Development of a Lifespan-Based Novel Composite Person Reported Outcome Measure Using Data From the CINRG Duchenne Natural History Study
Abstract
Development of novel technologies and therapeutic agents to treat Duchenne muscular dystrophy (DMD) have increased interest by regulatory bodies such as the Food and Drug Administration in the development of clinically-meaningful study endpoints for clinical trials. There is a need for the development of person-reported outcome (PRO) instruments that target a broad range of developmental and functional ability while effectively evaluating treatment effects in clinical trials.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2018
- Accession Number
- AD1070351
Entities
People
- Craig M. McDonald
- Erik Henricson
Organizations
- University of California